State-transition modeling: A report of the ISPOR-SMDM modeling good research practices task force-3

Value in Health

Volumn 15, Issue 6, 2012, Pages 812-820

  Siebert, Uwe ^a,b,c   Alagoz, Oguzhan ^d   Bayoumi, Ahmed M ^e   Jahn, Beate ^a,b   Owens, Douglas K ^f,g   Cohen, David J ^h   Kuntz, Karen M ⁱ  

^a UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^b Oncotyrol Center for Personalized Cancer Medicine   (Austria)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^g STANFORD UNIVERSITY   (United States)

^h UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

Author keywords

decision analytic modeling; guidelines; Markov models; state transition modeling

Indexed keywords

ARTICLE; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; DECISION SUPPORT SYSTEM; DIAGNOSTIC PROCEDURE; ECONOMIC EVALUATION; HEALTH CARE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH PROGRAM; HIDDEN MARKOV MODEL; HUMAN; LIFE EXPECTANCY; META ANALYSIS (TOPIC); MONTE CARLO METHOD; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; QUALITY OF LIFE; RELIABILITY; RISK ASSESSMENT; SCREENING; SIMULATION; STATE TRANSITION MODELING; STATISTICAL MODEL; SYSTEMATIC REVIEW (TOPIC); VALIDATION PROCESS;

ADVISORY COMMITTEES; COMPARATIVE EFFECTIVENESS RESEARCH; CONSENSUS; DECISION MAKING, COMPUTER-ASSISTED; EVIDENCE-BASED PRACTICE; GUIDELINES AS TOPIC; MARKOV CHAINS; MODELS, THEORETICAL;

EID: 84866349141     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.06.014     Document Type: Article

References (56)

1. J.J. Caro, A.H. Briggs, U. Siebert Modeling good research practices - overview: A report of the ISPOR-SMDM modeling good research practices task force-1 Value Health 15 2012 796 803
2. M. Roberts, L.B. Russell, A.D. Paltiel Conceptualizing a model: A report of the ISPOR-SMDM modeling good research practices task force-2 Value Health 15 2012 804 811
3. J. Karnon, J.E. Stahl, A. Brennan Modeling using discrete event simulation: A report of the ISPOR-SMDM modeling good research practices task force-4 Value Health 15 2012 821 827
4. R.J. Pitman, D. Fisman, G.S. Zaric Dynamic transmission modeling: A report of the ISPOR-SMDM modeling good research practices task force-5 Value Health 15 2012 828 834
5. A.H. Briggs, M.C. Weinstein, E. Fenwick Model parameter estimation and uncertainty: A report of the ISPOR-SMDM modeling good research practices task force-6 Value Health 15 2012 835 842
6. D.M. Eddy, W. Hollingworth, J.J. Caro Model transparency and validation: A report of the ISPOR-SMDM modeling good research practices task force-7 Value Health 15 2012 843 850
7. J.R. Beck, S.G. Pauker The Markov process in medical prognosis Med Decis Making 3 1983 419 458
8. F.A. Sonnenberg, J.R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 1993 322 338
9. M. Spielauer Dynamic microsimulation of health care demand, health care finance and the economic impact of health behaviours: survey and review Int J Microsimuation 1 2007 35 53
10. B. Groot Koerkamp, M.C. Weinstein, T. Stijnen Uncertainty and patient heterogeneity in medical decision models Med Decis Making 30 2010 194 205
11. M.C. Weinstein Recent developments in decision-analytic modelling for economic evaluation Pharmacoeconomics 24 2006 1043 1053
12. M.G.M. Hunink, P. Glasziou, J.E. Siegel Decision Making in Health and Medicine: Integrating Evidence and Values 2001 Cambridge University Press United Kingdom
13. J.J. Caro Pharmacoeconomic analysis using discrete event simulation Pharmacoeconomics 23 2005 323 332
14. U. Siebert When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econom 4 2003 143 150
15. N.F. Col, M.H. Eckman, R.H. Karas Patient-specific decisions about hormone replacement therapy in postmenopausal women JAMA 277 1997 1140 1147
16. D.M. Eddy Screening for Cancer: Theory, Analysis and Design 1980 Prentice-Hall, Inc. Englewood Cliffs, NJ
17. L.B. Russel Educated Guesses: Making Policy About Medical Screening Tests 1994 University of California Press Los Angeles
18. E. Grill, F. Hessel, U. Siebert Comparing the clinical effectiveness of different new-born hearing screening strategies: a decision analysis BMC Public Health 5 2005 12
19. E. Gutierrez de Mesa, I. Hidalgo, P. Christidis Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children Mol Diag Ther 11 2007 313 320
20. L.M. Meckley, J.M. Gudgeon, J.L. Anderson A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing Pharmacoeconomics 28 2010 61 74
21. W.H. Rogowski The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study Med Decis Making 29 2009 224 238
22. S.J. Goldie, J.J. Kim, E. Myers Cost-effectiveness of cervical cancer screening Vaccine 24 Suppl. 2006 S164 S170
23. J.M. Lee, P.M. McMahon, C.Y. Kong Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers Radiology 254 2010 793 800
24. G. Sroczynski, P. Schnell-Inderst, N. Muhlberger Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis Eur J Cancer 47 2011 1633 1646
25. A.G. Zauber, I. Lansdorp-Vogelaar, A.B. Knudsen Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force Ann Intern Med 149 2008 659 669
26. G.D. Sanders, A.M. Bayoumi, V. Sundaram Cost effectiveness of screening for HIV in the era of highly active antiretroviral therapy N Engl J Med 352 2005 570 585
27. G.D. Sanders, A.M. Bayoumi, M. Holodniy, D.K. Owens Cost effectiveness of HIV screening in patients older than 55 years of age Ann Intern Med 148 2008 889 903
28. T.A. Trikalinos, U. Siebert, J. Lau Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations Med Decis Making 29 2009 E22 E29
29. M.K. Gould, G.D. Sanders, P.G. Barnett Cost effectiveness of alternative management strategies for patients with solitary pulmonary nodules Ann Intern Med 138 2003 724 735
30. M.G.M. Hunink, K.M. Kuntz, K.E. Fleischmann, T.J. Brady Noninvasive imaging for the diagnosis of coronary artery disease: focusing the development of new diagnostic technology Ann Intern Med 131 1999 673 680
31. D.J. Cohen, A. Bakhai, C. Shi Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial Circulation 110 2004 508 514
32. G.D. Sanders, M.A. Hlatky, D.K. Owens Cost effectiveness of the implantable cardioverter defibrillator (ICD) in primary prevention of sudden death N Engl J Med 353 2005 1471 1478
33. U. Siebert, G. Sroczynski German Hepatitis C Model (GEHMO) Group HTA Expert Panel on Hepatitis C Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security Int J Tech Assess Health Care 21 2005 55 65
34. K.A. Freedberg, J.A. Scharfstein, G.R. Seage III The cost-effectiveness of preventing AIDS-related opportunistic infections JAMA 279 1998 130 136
35. T.G.K. Bentley, M.C. Weinstein, K.M. Kuntz Effects of categorizing continuous variables in decision-analytic models Med Decis Making 29 2009 549 556
36. J.M. Lee, D.B. Kopans, P.M. McMahon Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging-Markov Monte Carlo decision analysis Radiology 246 2008 763 771
37. P.M. Clarke, A.M. Gray, A. Briggs A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) outcomes model Diabetologia 47 2004 1747 1759
38. J.M. Robins, M.A. Hernán, U. Siebert Estimations of the effects of multiple interventions M. Ezzati, A.D. Lopez, A. Rodgers, C.J.L. Murray, Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors Vol. 1 2004 World Health Organization Geneva 2191 2230
39. M.L. Puterman Markov Decision Processes: Discrete Stochastic Dynamic Programming (Wiley Series in Probability and Statistics 1994 John Wiley and Sons New York
40. O. Alagoz, H. Hsu, A.J. Schaefer, M.S. Roberts Markov decision processes: a tool for sequential decision making under uncertainty Med Decis Making 30 2010 474 483
41. S. Dewilde, R. Anderson The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer Med Decis Making 24 2004 486 492
42. T.A. Lieu, R.J. Gurley, R.J. Lundstrom Projected cost-effectiveness of primary angioplasty for acute myocardial infarction J Am Coll Cardiol 30 1997 1741 1750
43. Berrington de Gonzalez, K.P. Kim, A.B. Knudsen Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis AJR Am J Roentgenol 196 2011 816 823
44. Primer on lead time, length and overdiagnosis bias. Effective Clinical Practice 1999 (March/April 1999) http://www.acponline.org/clinical-information/ journals -publications/ecp/primers/marapr99.htm Accessed January 17, 2012
45. K.M. Kuntz, S.J. Goldie Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias Med Decis Making 22 2002 218 227
46. G.S. Zaric The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysis Med Decis Making 23 2003 379 386
47. F.A. Sonnenberg, M.S. Roberts, J. Tsevat Toward a peer review process for medical decision analysis models Med Care 32 7, Suppl. 1994 JS52 JS64
48. D.K. Owens, K.N. Lohr, M. Helfand Grading the strength of a body of evidence when comparing medical interventions - AHRQ and the effective health care program J Clin Epidemiol 63 2010 513 523
49. G.H. Guyatt, A.D. Oxman, H.J. Schunemann GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology J Clin Epidemiol 64 2011 380 382
50. H. Balshem, M. Helfand, H.J. Schunemann GRADE guidelines, 3: rating the quality of evidence J Epidemiol 64 2011 401 406
51. D.K. Miller, S.M. Homan Determining transition probabilities: confusion and suggestions Med Decis Making 14 1994 52 58
52. K.M. Kuntz, M.C. Weinstein Life expectancy biases in clinical decision modeling Med Decis Making 15 1995 158 169
53. E. Cox, B.C. Martin, T. Van Staa Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II Value Health 12 2009 1053 1061
54. M.L. Johnson, W. Crown, B.C. Martin Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III Value Health 12 2009 1062 1073
55. K.M. Kuntz, M.C. Weinstein Modelling in economic evaluation M. Drummond, A. McGuire, Economic Evaluation in Health Care: Merging Theory with Practice 2001 Oxford University Press New York
56. N.K. Stout, S.J. Goldie Keeping the noise down: common random numbers for disease simulation modeling Health Care Manage Sci 11 2008 399 406